12 August 2015
Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Notice of Interim Results
Winsford, UK, 12 August 2015 – Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, will announce its interim results for the six months ended 30 June 2015 on Wednesday 9 September 2015.
A briefing for analysts will be held at 9.30am on the day of the results. Please contact Consilium Strategic Communications for further details.
– Ends –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director |
+44 (0) 1606 545508 |
|
Consilium Strategic Communications Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys |
+44 (0) 20 3709 5700 AMS@consilium-comms.com |
|
Investec Bank PLC (NOMAD & Broker) Gary Clarence / Daniel Adams / Patrick Robb
|
+44 (0) 20 7597 5970 |
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.
This information is provided by RNS
END
NOREFLFFEVFEBBL